The UK-based company is aiming to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors.

Immodulon is developing IMM-101, a heat-killed formulation of the mycobacterium M. obuense, as a broad-spectrum immunomodulatory agent that has promising potential in a range of difficult-to-treat tumours including those considered to be immunologically “cold,” such as pancreatic ductal adenocarcinoma.

The company has generated promising, positive Phase II data with IMM-101 in pancreatic cancer in combination with gemcitabine. These data show that IMM-101 is safe and effective, prolonging progression-free survival for a sub-group of patients with metastatic disease compared to gemcitabine alone. IMM-101 is due to enter a pivotal pancreatic cancer study.